KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBIT Margin: 2009-2025

Historic EBIT Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to 12.83%.

  • Acadia Pharmaceuticals' EBIT Margin rose 20.00% to 12.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.01%, marking a year-over-year increase of 1093.00%. This contributed to the annual value of 24.10% for FY2024, which is 3420.00% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' EBIT Margin stood at 12.83%, which was up 4.87% from 12.24% recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' EBIT Margin ranged from a high of 59.13% in Q4 2024 and a low of -97.88% during Q1 2022.
  • In the last 3 years, Acadia Pharmaceuticals' EBIT Margin had a median value of 12.24% in 2025 and averaged 6.29%.
  • Per our database at Business Quant, Acadia Pharmaceuticals' EBIT Margin spiked by 5,961bps in 2021 and then tumbled by 3,521bps in 2022.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' EBIT Margin stood at -34.15% in 2021, then skyrocketed by 40bps to -33.75% in 2022, then soared by 4,887bps to 15.12% in 2023, then skyrocketed by 4,401bps to 59.13% in 2024, then climbed by 20bps to 12.83% in 2025.
  • Its EBIT Margin was 12.83% in Q3 2025, compared to 12.24% in Q2 2025 and 7.90% in Q1 2025.